This prospective, randomized, doubleblind study compared the effects of dexmedetomidine and remifentanil on haemodynamic stability, sedation and postoperative pain control in the postanaesthetic care unit (PACU). Fifty consecutive patients scheduled for total laparoscopic hysterectomy were randomly assigned to receive infusions of either dexmedetomidine (1 µg/kg) i.v. over 10 min followed by 0.2 -0.7 µg/kg per h continuous i.v. infusion or remifentanil (0.8 -1.2 µg/kg) i.v. over 1 min followed by 0.05 -0.1 µg/kg i.v. per min, starting at the end of surgery to the time in the PACU. Modified observer's assessment of alertness scores were significantly lower in the dexmedetomidine group than in the remifentanil group at 0, 5 and 10 min after arrival in the PACU. Blood pressure and heart rate in the dexmedetomidine group were significantly lower than that recorded in the remifentanil group in the PACU. Dexmedetomidine, at the doses used in this study, had a significant advantage over remifentanil in terms of postoperative haemodynamic stability.
Introduction
The highly selective α 2 -receptor agonist dexmedetomidine has sedative properties and is used in the operating room and the intensive care unit for sedation. 1, 2 Dexmedetomidine has not been associated with respiratory depression, despite profound levels of sedation. 3 In addition, dexmedetomidine has analgesia-sparing properties and provides anxiolysis and cooperative sedation without respiratory depression. 4, 5 It decreases sympathetic outflow from the central nervous system in a dose-dependent manner and has analgesic effects that are best described as opioidsparing. 6 Consistent with its pharmacological effects, dexmedetomidine decreases heart HS Jung, JD Joo, YS Jeon et al.
Comparison of dexmedetomidine and remifentanil for postoperative pain
rate and arterial pressure. These haemodynamic changes are associated with a reduction in noradrenaline and adrenaline levels in plasma. 7 Dexmedetomidine has also been shown consistently to reduce opioid requirements by 30 -50%. 8 The analgesic potential of α 2 -agonists does not, however, approximate the potency of opioids. Nevertheless, in certain types of pain in which opioid relief is suboptimal, such as in neuropathic pain, α 2 -agonists may offer specific advantages. 9 Because of these properties, dexmedetomidine might prove useful in the postoperative period for patients undergoing major surgical procedures that involve significant pain.
Remifentanil is a selective, ultra-shortacting µ-opioid receptor agonist with an analgesic potency similar to that of fentanyl and a blood-brain equilibration time similar to that of alfentanil. 10, 11 At St Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea, opioids such as fentanyl or remifentanil are commonly used for anaesthetic induction, maintenance and postoperative pain control. Antiemetic agents and non-steroidal anti-inflammatory drugs are also used for preventing postoperative nausea and vomiting via a patient-controlled analgesia (PCA) device that is made available to patients soon after completion of surgery.
The present paper compared the efficacy of dexmedetomidine with remifentanil, with respect to haemodynamic stability, achievement of hypnosis and sedation, and postoperative pain control, immediately after completion of total laparoscopic hysterectomy.
Patients and methods

STUDY POPULATION
This prospective, randomized, double-blind pilot study included consecutive female patients aged 18 -65 years who were classified as physical status I -II according to the American Society of Anesthesiologists (ASA). 12 These patients were scheduled to undergo elective total laparoscopic hysterectomy with general anaesthesia at the Department of Anaesthesology and Pain Medicine, St Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea, between October 2010 and April 2011. Patients with severe bronchopulmonary disease, cardiovascular, endocrinological, neuropathological, renal or hepatic disorders, an allergy to opioids, or those who were currently using analgesics or psychoactive drugs, were excluded from the study.
The study protocol was approved by the Ethics Committee of St Vincent's Hospital and written informed consent was obtained from all the study participants.
STUDY DESIGN AND TREATMENT
Before surgery, the patients were divided randomly into two groups using a computergenerated random-number table and sealedenvelopes. In the operating room, routine monitoring included three-lead electrocardiogram, non-invasive systolic blood pressure (SBP) and diastolic blood pressure (DBP), mean arterial pressure, heart rate, respiratory rate, pulse oximetry and endtidal carbon dioxide level.
Electrodes . Anaesthesia was maintained with oxygen at 2 l/min, nitrous oxide at 3 l/min and 6 -7 vol.% of desflurane with rocuronium. The low solubility of desflurane in blood and body tissues causes a very rapid wash-in and wash-out of the anaesthetic. Thus, desflurane, which has a blood/gas partition coefficient (0.42) even lower than that of nitrous oxide (0.47), was used in the present study. The end-tidal carbon dioxide level was maintained at 35 -40 mmHg.
The study drugs were administered at a point when the pain threshold is beginning to reduce, i.e. at 60 min intraoperatively. A single dose of ketorolac 30 mg i.v. was given to all patients at the end of surgery and additional study drugs were administered according to group designation. Starting at the end of surgery to the time in the postanaesthetic care unit (PACU), patients received either a loading dose of dexmedetomidine 1 µg/kg i.v. administered over 10 min followed by a continuous infusion of 0.2 -0.7 µg/kg per h, or a loading dose of remifentanil 0.8 -1.2 µg/kg i.v. given over 1 min followed by continuous infusion of 0.05 -0.1 µg/kg per min. The doses in both groups were considered sedative doses. A decreased heart rate, < 50 beats/min, was treated with atropine 10 µg/kg i.v. bolus injection. A SBP < 80 mmHg was treated with ephedrine 5 mg i.v. bolus injection. The total doses of remifentanil and dexmedetomidine administered during the study were recorded.
Anaesthetic gases were turned off 5 min before the completion of surgery and, at the end of surgery, the patients were given pyridostigmine 10 mg and glycopyrrolate 0.2 mg i.v. bolus injection. Patients were ventilated with 100% oxygen at 5 l/min from when anaesthetic gases were turned off until they were fully awake and had recovered from the muscle relaxation.
STUDY ASSESSMENT
Blood pressure and heart rate were measured every 5 min and were recorded at t0 (before induction), t1 (after induction), t2 (after incision), t3 (operation for 15 min), t9 (operation for 90 min), R0 (arrival at the recovery room), and R5, R10, R15, R20, R25 and R30 (5, 10, 15, 20, 25 and 30 min after arrival at the recovery room, respectively).
Visual analogue scale (VAS) scores for preor postoperative pain were measured on a scale of 0 -10, where 0 represented no pain and 10 represented worst possible pain. A modified observer's assessment of alertness (OAA/S) score 13,14 of sedation and hypnosis was measured on arrival at operation and in the PACU (0 -5 scale, where 0 represents no response to noxious stimulus, and 5 represents awake and responsive to their name when spoken in a normal tone).
The incidence of postoperative side-effects (nausea, vomiting, dry mouth, shivering, hypotension, bradycardia) in both groups was recorded in the PACU. The BIS, VAS scores, modified OAA/S scores of sedation, vital signs, respiratory rates and end-tidal carbon dioxide levels were also measured simultaneously. 15, 16 
STATISTICAL ANALYSES
Statistical analyses were performed using GraphPad Prism Software, version 5.0 (GraphPad Software Inc., San Diego, CA, USA). The unpaired t-test was used for comparisons between groups in age, weight, height, ASA status, duration of surgery and duration of anaesthesia. The overall significance of the results was examined using one-way analysis of variance and a HS Jung, JD Joo, YS Jeon et al.
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Bonferroni post-hoc test was used for multiple comparisons. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 50 healthy Caucasian women were recruited to the study: 25 in each group. Both groups were similar with respect to age, weight, height, ASA status, operation duration and duration of anaesthesia (Table  1) . Patients in the dexmedetomidine group received a total mean ± SD dose of 134.33 ± 42.67 µg dexmedetomidine, whereas those in the remafentanil group received a mean ± SD dose of 429 ± 35 µg remifentanil.
There were no significant differences in the incidence of side-effects between the two groups ( Table 2) . Such effects were observed mainly during the immediate postoperative period (0 -30 min after surgery).
Modified OAA/S scores of sedation were significantly lower in the dexmedetomidine group compared with the remafentanil group at R0, and at R5 and R10 (P < 0.05 for all comparisons) (Fig. 1A) 
Data presented as n (%). There were no statistically significant between-group differences (P > 0.05); one-way analysis of variance. a Hypotension: systolic blood pressure < 80 mmHg or diastolic blood pressure < 50 mmHg or < 30% of the level before drug injection. (Fig. 1B) . Changes in the BIS were not significantly different between the groups at all times from t0 (before induction time) to R30 (30 min after arrival at recovery room) (Fig. 2) .
After the injection of study drugs, SBP, DBP and HR were significantly lower in the dexmedetomidine group compared with the remafentanil group from t6 (operation time 75 min) to R10 (P < 0.05 for all comparisons) (Fig. 3) .
Discussion
Dexmedetomidine was recently introduced in the Republic of Korea but there have been many published reports of its sedative and hypnotic effects over the past 20 years from other countries. 4, 15, 17, 18 Dexmedetomidine 
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has been implemented as a sedative and hypnotic for patients undergoing procedures without the need for tracheal intubation. For example, dexmedetomidine has been used for sedation in monitored anaesthesia care, such as fibreoptic bronchoscopy, dental, ophthalmological, head and neck procedures, neuro-and vascular surgery, computed tomography and magnetic resonance imaging, awake fibreoptic intubation techniques and in paediatric patients who require sedation. 19 -22 Unlike other sedatives, dexmedetomidine-induced sedation allows the patient to open their eyes to facilitate responses to verbal stimulation and communication, with patients showing normal cognitive abilities. After surgery or other procedures, dexmedetomidine can be used without restriction during physical examination to identify the patient's general condition and neurological status.
Dexmedetomidine has sedative and analgesia-sparing effects via central actions in the locus coeruleus and in the dorsal horn of the spinal cord; 23 it inhibits noradrenaline release causing an attenuation of excitation in the central nervous system, especially in the locus coeruleus. 24 Dexmedetomidine reduces opioid requirements by 30 -50% and has a better safety profile than opioids for sedation. 25 At St Vincent's Hospital, after surgery and admission to the recovery room, all patients receive titrated i.v. infusions of fentanyl with a loading dose of 25 -100 µg, a continuous dose of 10 -60 µg/h, an intermittent dose of 10 -50 µg/h and a lockout interval of 6 -8 min with PCA for postoperative pain control.
FIGURE 2:
Changes in bispectral index (BIS) for the remifentanil-ketorolac and dexmedetomidine-ketorolac groups, showing no statistically significant differences between the two groups (P > 0.05; one-way analysis of variance with a Bonferroni post hoc test; BIS value 0, electroencephalographic silence; BIS value near 100, expected value in fully awake adult; BIS value between 40 and 60, general anaesthesia; t0, before induction; t1, after induction; t2, after incision; t3, operation 15 min; t4, operation 30 min; t5, operation 60 min; t6, operation 75 min; t7, operation 80 min; t8, operation 85 min; t9, operation 90 min; R0, arrival at recovery room; R5, R10, R15, R20, R25 and R30, 5, 10, 15, 20, 25 and 30 min after arrival at recovery room, respectively; mean ± SD) 
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Fentanyl, a synthetic opioid narcotic, is highly lipid soluble and rapidly reaches opioid receptors. 26 Choi et al. 27 reported that dexmedetomidine was more effective than fentanyl in terms of the postoperative haemodynamic stability in the PACU. Remifentanil infusion can provide analgesia and sedation in critically-ill patients. 28, 29 Low doses of remifentanil (up to 0.05 µg/kg per min, i.v.) are useful in critically-ill patients in order to achieve calmness and sedation, but increasing the dose can inhibit respiratory rate and may require controlled mechanical ventilation. 
According to clinical needs, sedation can be titrated to different targets, e.g. to obtain calmness or loss of consciousness, to decrease sympathetic tone or even to inhibit respiratory rate. 30 This is characteristic of dexmedetomidine, which does not induce respiratory depression, 3 and can therefore be utilized in regional anaesthesia, intubation and extubation during arousal. A BIS value of 0 equals electroencephalographic (EEG) silence, while near 100 is the expected value in a fully awake adult, and between 40 and 60 indicates a level for general anaesthesia. 31, 32 Desflurane was chosen for the present study as it has a minimal effect on the BIS score after surgery. Unlike γ-aminobutyric acid mimetic drugs, the primary site of α 2 -agonist sedative action does not appear to be the cerebral cortex: these agents appear to target a different type of sedation. 33 A sedative dose infusion of dexmedetomidine at 0.6 µg/kg per h produces EEG changes that correspond to a BIS of 60 (moderate to deep sedation). 34 Thus, the BIS score in the present study suggests that EEG parameters may be inadequate to assess the depth of anaesthesia in the presence of α 2 -agonists. As a consequence, the BIS scores for dexmedetomidine and other opioids appear to show similar results in sedative doses. Dexmedetomidine usually inhibits the sympathetic nervous system, acting on the brain stem below the cerebral cortex. The haemodynamic stability of dexmedetomidine can show different patterns of reducing blood pressure and heart rate, depending on the patient's general condition. 34 Administration of atipamezole, an α 2 -adrenergic antagonist, should completely reverse the sedative and analgesic effects, return the heart rate to normal and prevent any further reductions in respiratory rate. 35, 36 It has been reported that atipamezole fully reversed the clinical effects of dexmedetomidine. 35, 36 There was no statistically significant difference in pain control between the two groups in the present study. Modified OAA/S scores of sedation were, however, significantly lower in the dexmedetomidine group compared with the remifentanil group. Patients on dexmedetomidine showed a level of haemodynamic stability normally observed when maintaining sedation states, despite being able to respond to verbal stimulation and reporting a little pain. They had the ability to communicate with normal cognition and had reduced postoperative nausea, vomiting and excitement, which suggests that dexmedetomidine demonstrates excellent attributes for an anaesthetic.
In conclusion, dexmedetomidine, at the doses used in this study, had a significant advantage over remifentanil in terms of postoperative haemodynamic stability in the PACU and demonstrated good pain control with patient awareness during sedation.
